Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Research Article

Synthesis, Cytotoxicity Evaluation and Molecular Docking of Fluorine Containing Hexahydroquinoline-3-Carbonitrile Derivatives

(E-pub Ahead of Print)
Author(s): Nishith Teraiya*, Subhas Karki and Ashlesha Chauhan

Article ID: e140122189603

DOI: 10.2174/1570163817666201229154848

open access plus

Abstract

Background: Fluorine containing Hexahydroquinoline-3-carbonitrile derivatives were found to have potent cytotoxicity. Further, Fluorine can modulate pharmacokinetic and pharmacodynamic profile of drugs. Hence, new derivatives containing fluorine were explored as potential cytotoxic agents.

Objective: Difluoro substituted compounds containing aromatic/heteroaromatic rings were designed, synthesized and screened for in vitro cytotoxicity on cancer cell lines. The active compounds were subjected to docking on Mcl-1 and ADME/T prediction.

Methods: The synthesized compounds were characterized using various spectral techniques like FT-IR, 1 H NMR, 13C NMR and Mass spectra. Compounds were screened for cytotoxicity on NCI-60 cell lines at National Cancer Institute. The active compounds were evaluated additionally by MTT and SRB assay.

Results: Compounds (6l and 6o) showed maximum cytotoxicity with (% GI) of 69 and 63.7 at 10 µM drug concentration respectively. Compound 6i showed potent cytotoxicity with GI50 of 7.2 µM against Ishikawa cell line. Compound 6o was nearly as active as reference with IC50 of 9.39 µM and 13.54 µM against HT-29 and HCT-116 respectively and compound 6l also showed equal potency to that of reference with IC50 of 9.66 µM against Caco-2. Compounds 6i, 6o and 6l showed high docking score suggesting their cytotoxicity. Further, ADME/T prediction revealed that all the compounds have drug likeness properties.

Conclusion: Enhanced lipophilic interaction of compounds due to presence of fluorine in compounds 6i and 6l was revealed during docking study. Compound 6i can be explored as a lead molecule against other endometrial cancer in futuristic drug development.

Keywords: Hexahydroquinoline-3-carbonitrile derivatives, cytotoxicity, NCI-60 cell lines, MTT assay, docking, venetoclax, imatinib


© 2022 Bentham Science Publishers | Privacy Policy